| 2016-11-21 06:09:14|
CFRX 06:09 11/21 11/21/16
ContraFect price target raised to $4.50 from $3.50 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for ContraFect to $4.50 after attending the inaugural Lysin Meeting at Rockefeller University. The analyst was impressed by the "significant fundamental biological progress" and broad potential applicability of lysins as a novel class of antibiotics. He reiterates an Overweight rating on ContraFect.